RECURRENT GRADE 3A FOLLICULAR LYMPHOMA
Clinical trials for RECURRENT GRADE 3A FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT GRADE 3A FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT GRADE 3A FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Immune-Targeting drug tested for Tough-to-Treat blood cancers
Disease control OngoingThis is an early-stage study to find the safest dose of an experimental immunotherapy drug called MEDI-570. It is for adults with specific types of advanced T-cell lymphoma that have come back or stopped responding to previous treatments. The main goals are to check for side effe…
Matched conditions: RECURRENT GRADE 3A FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New hope for patients when CAR-T fails: immunotherapy trial targets stubborn blood cancers
Disease control OngoingThis study is testing whether the immunotherapy drug nivolumab can help control blood cancers that have returned, stopped responding, or are still detectable after a patient has already received CAR-T cell therapy. It is for adults with specific types of lymphoma, leukemia, or mu…
Matched conditions: RECURRENT GRADE 3A FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Early trial tests new Two-Drug attack on Tough-to-Treat blood cancers
Disease control OngoingThis early-stage study is testing a combination of two drugs, pembrolizumab and vorinostat, for patients with certain types of lymphoma that have come back or stopped responding to previous treatments. The main goals are to find the safest dose and understand the side effects of …
Matched conditions: RECURRENT GRADE 3A FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New combo therapy aims to fight back against stubborn blood cancer
Disease control TerminatedThis study is testing whether a combination of two drugs, epcoritamab and tazemetostat, is safe and effective for adults with follicular lymphoma that has come back or hasn't responded to previous treatments. The goal is to see if this two-drug approach can help control the cance…
Matched conditions: RECURRENT GRADE 3A FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC
-
New combo therapy tested for Tough-to-Treat lymphomas
Disease control OngoingThis study is testing whether combining the immunotherapy drug pembrolizumab with the standard antibody rituximab (with or without the drug lenalidomide) can help control lymphoma that has come back after previous treatment. It is for adults with specific types of B-cell lymphoma…
Matched conditions: RECURRENT GRADE 3A FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 27, 2026 12:37 UTC